ReviewThe AAPS journal2020
The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules.
Review in The AAPS journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Spray Drying for Pharmaceutical Raw Materials: A Systematic Review on Enhancing Bioavailability and Stability.Drug design, development and therapy · 2025Pooled it
- Aligning biopharma and academic partnerships to advance drug delivery technologies: insights from a multidisciplinary panel.Drug delivery and translational research · 2026Article
- Bispecific and multispecific immune engagers for redirecting innate and adaptive immunity against hematologic cancers.Discover oncology · 2026Review
- Keeping up with a Quickly Diversifying Pharmaceutical Landscape.ACS measurement science au · 2024Review
- Exploring Orodispersible Films Containing the Proteolysis Targeting Chimera ARV-110 in Hot Melt Extrusion and Solvent Casting Using Polyvinyl Alcohol.Pharmaceutics · 2024Article
- Use of Poly(vinyl alcohol) in Spray-Dried Dispersions: Enhancing Solubility and Stability of Proteolysis Targeting Chimeras.Pharmaceutics · 2024Article
- Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs.Communications medicine · 2024Article
- Delivery of therapeutic small interfering RNA: The current patent-based landscape.Molecular therapy. Nucleic acids · 2022Article
- Macrocyclic DNA-encoded chemical libraries: a historical perspective.RSC chemical biology · 2022Review
- Cell Surface Transporters and Novel Drug Developments.Frontiers in pharmacology · 2022Review
- Evidence supporting the oncogenic role of BAZ1B in colorectal cancer.American journal of cancer research · 2022Article
- Late-Stage Amination of Drug-Like Benzoic Acids: Access to Anilines and Drug Conjugates through Directed Iridium-Catalyzed C-H Activation.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- Drug Design: Where We Are and Future Prospects.Molecules (Basel, Switzerland) · 2021Review
- Amorphous Solid Dispersions (ASDs): The Influence of Material Properties, Manufacturing Processes and Analytical Technologies in Drug Product Development.Pharmaceutics · 2021Article
- Application of Machine Learning in Translational Medicine: Current Status and Future Opportunities.The AAPS journal · 2021Article
- Network pharmacology and molecular docking study on the active ingredients of qidengmingmu capsule for the treatment of diabetic retinopathy.Scientific reports · 2021Article
- Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.International journal of molecular sciences · 2021Review
- Therapeutic Advances in Oncology.International journal of molecular sciences · 2021Review
- Are we ready to design oral PROTACs®?ADMET & DMPK · 2021Article
- Cyanobacteria and Eukaryotic Microalgae as Emerging Sources of Antibacterial Peptides.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The druggability and developability space is rapidly evolving in the post-genomic era. In the past, Lipinski's rule-of-five (Ro5) emerged and served as a guide for drug-like molecule design for oral delivery in the traditional druggable target space. In contrast, in this new era, a transition is occurring in drug discovery towards novel approaches to bind and modulate challenging biological targets that have led to transformative treatments for patients. Consequently, drugging novel targets using a variety of emerging molecular modalities, namely beyond the Ro5 (bRo5) small molecules (such as protein-protein interaction modulators, protein-targeted chimeras, or PROTACs), peptide/peptidomimetics, and nucleic acid-based modalities, have become a key focus in drug discovery. Herein, the emerging druggability and developability space is discussed side by side to build a general understanding of the potential development challenges of these novel modalities. An overview is provided on the evolving novel targets and molecular modalities, followed by a detailed analysis of the druggability aspects as well as the strategies used to progress drug candidate, and the trending chemistry and formulation strategies used to assess developability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.